Condition category
Eye Diseases
Date applied
22/03/2017
Date assigned
27/03/2017
Last edited
06/11/2017
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
Glaucoma is an eye condition where the optic nerve, which connects the eye to the brain, becomes damaged over time. Many cases are caused by increased pressure in the eye (intraocular pressure) due to a build-up of fluid. Glaucoma can result in blindness if left untreated and as such it is extremely important to diagnose and treat the condition. Usually doctors treat the first symptoms of glaucoma by prescribing eye drops. Unfortunately, there can be side effects associated with the use of these eye drops and there are reports of non-compliance due to difficulties in inserting these drops, all of which can impact on how effective this treatment is. Selective Laser Trabeculoplasty (SLT) is a laser treatment that opens up the drainage tubes inside the eye, allowing more fluid to drain out of the eye, reducing the intraocular pressure and helping to control the progression of the disease. SLT is a technique routinely carried out by glaucoma specialists. It is conducted using a special type of lens (goniolens) that gently sits on the front surface of the eye. The procedure takes about 5 minutes. A new treatment called Direct Selective Laser Trabeculoplasty (DSLT) is performed directly, without there being any need to use a goniolens which sits on the eye. It is a shorter and simpler technique to perform compared to the standard SLT technique. In early studies, it has been shown to have similar pressure reducing abilities to the standard SLT technique. The aim of this study is to assess how well the new automated DSLT device developed by BELKIN Laser Ltd, Israel works in comparison with standard SLT, and determine whether it is as effective at reducing intraocular pressure.

Who can participate?
Patients aged over 40 with mild to moderate open angle glaucoma

What does the study involve?
The treating ophthalmologist performs a complete eye examination of each participant. This includes vision assessment, intraocular pressure and visual field measurements, examination of the back of the eyes and a check of the overall health of the eyes. On the eligibility visit, the intraocular pressure is checked and participants are randomly allocated to receive either SLT (the standard treatment) or DSLT (the new treatment). Intraocular pressure is measured after 3, 6, and 12 months

What are the possible benefits and risks of participating?
Benefits to taking part in this study include a 50% chance of receiving the new DSLT technique which could result in a speedier treatment, less inflammation and less discomfort during and following treatment. The risks of taking part in the study are the same as those associated with the standard laser procedure, including eye inflammation, discomfort and pressure spikes. Inflammatory reactions can affect either the front (more common) and/or back of the eye (retina – less common). The inflammation is usually mild to moderate and short lived, usually reducing within 24 hours following treatment and gone within 5 days. Another risk associated with laser trabeculoplasty treatment is pressure spikes after the operation. These usually occur quite soon after the procedure (1-2 hours) and careful patient selection and preventative medication can be given to avoid their occurrence.

Where is the study run from?
1. Queen's University Belfast (UK)
2. The University of Genova (Italy)

When is the study starting and how long is it expected to run for?
July 2017 to February 2019

Who is funding the study?
Horizon 2020 Framework Programme (Belgium)

Who is the main contact?
Dr Masha Dobkin-Bekman

Trial website

Contact information

Type

Public

Primary contact

Dr Masha Dobkin-Bekman

ORCID ID

Contact details

Habarzel 27
Tel-Aviv
6971039
Israel

Type

Scientific

Additional contact

Prof Michael Belkin

ORCID ID

http://orcid.org/0000-0002-6174-1182

Contact details

4 Alonim St.
Givat Shmuel
5404402
Israel

Type

Scientific

Additional contact

Prof Nathan Congdon

ORCID ID

http://orcid.org/0000-0001-9866-3416

Contact details

Queen's University Belfast
Belfast
BT7 1NN
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

GLAUrious-2017-01

Study information

Scientific title

Direct selective laser trabeculoplasty (DSLT) in open angle glaucoma (OAG): a randomized controlled trial

Acronym

GLAUrious

Study hypothesis

Direct Selective Laser Trabeculoplasty (DSLT) is not inferior to Selective Laser Trabeculoplasty (SLT) in reducing intraocular pressure (IOP).

Ethics approval

1. North West - Greater Manchester West Research Ethics Committee, ref: 17/NW/0358.
2. Regional Ethics Committee- Comitato Etico Regionale della Liguria, IRCCS San Martino, 27/07/2017, ref: 287REG2017

Study design

Randomized controlled masked (investigator(s)) study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Glaucoma

Intervention

Eligible patients who sign the informed consent will be enrolled at each of the study sites, and undergo a washout (in the case of being medicated). After washout there will be a baseline visit, where continued eligibility is confirmed. Following confirmation of continued eligibility, 50% of patients are randomized to each treatment group (DSLT or SLT). Randomization will be to a pre-determined randomization list. The un-masked investigator(s) will open the envelope corresponding to the subject ID and administer the treatment as indicated by the randomization envelope. Only one eye per participant will be included in the study and they will be treated using either DSLT or SLT as per the randomized treatment allocation. The ophthalmologist(s) who perform the follow up (3, 6, and 12 months) will be masked as to the nature of the treatment the patient underwent.

Intervention type

Device

Phase

Drug names

Primary outcome measures

Primary effectiveness endpoint:
The primary effectiveness endpoint is the difference between the two treatment groups between the mean (washed out for medicated patients) baseline IOP and the mean (washed out for medicated patients) IOP measured at 6 months.
Eligible patients on medications will be washed out at both treatment groups. The mean intraocular pressure (IOP) at baseline before the treatment and washed out IOP at 6 months will be measured by Goldmann Applanation Tonometry. The difference between the two treatment groups in change between mean washout baseline and 6-month IOP will be estimated.

Safety endpoints:
Adverse events

Secondary outcome measures

1. Mean percentage reduction in IOP, measured by Goldmann Applanation Tonometry at 3, 6, and 12 months
2. Number of medications being taken for each eye at baseline (before treatment) and 12 months

Overall trial start date

01/07/2017

Overall trial end date

02/02/2019

Reason abandoned

Eligibility

Participant inclusion criteria

1. Age 40 years or older, with visual acuity > 6/60 in both eyes
2. Primary open angle glaucoma including exfoliative or pigmentary glaucoma
3. IOP ≥ 22mmHg to ≤35mmHg (in the case of a medicated patient at the baseline visit following washout and in the case of a naïve (newly diagnosed) patient at the time of screening)
4. Gonioscopically visible scleral spur for 360 degrees without indentation
5. Ability to visualize the peri-limbal sclera for 360 degrees (using a speculum)
6. Willing and able to participate in the 12-month study, to comply with the study procedures and to adhere to the follow-up schedule
7. Participant capable of giving informed consent

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

96

Participant exclusion criteria

Individuals with the following characteristics will be excluded from the study (unless specified otherwise, all ocular criteria refer to the study eye only):
1. Contraindications to conventional laser trabeculoplasty (e.g. corneal abnormalities, etc)
2. Angle Closure Glaucoma
3. Congenital or developmental glaucoma
4. Secondary glaucoma except exfoliative or pigmentary glaucoma
5. Presence of any Peripheral Anterior Synechiae (PAS) in the study eye
6. Inability to conduct a reliable visual field (defined as fixation losses, false positives or false negatives greater than 33%)
7. Any of the following visual field findings using the Humphrey visual field analyzer the SITA-standard 24-2 program:
7.1. A visual field MD of less than -12dB
7.2. Greater than or equal to 75% of points depressed below the 5% level and greater than or equal to 50% of points depressed below the 1% level on the PD plot
7.3. At least 50% of points (i.e 2 or more) within the central 5 degrees with a sensitivity ≤0dB on the decibel plot
7.4. Points within the central 5 degrees of fixation with a sensitivity <15 dB in both hemifields on the decibel plot
8. A visual field MD of less than -12dB in the fellow eye
9.Cup:Disc Ratio of more than 0.8
10. More than two hypotensive mediations required
11. Prior incisional or laser glaucoma surgery
12. Prior corneal refractive surgery
13. Complicated cataract surgery ≤ 6 months prior to enrollment
14. Presence of visually significant cataract in the opinion of the investigator
15. Clinically significant disease in either eye as determined by the Investigator
16. Clinically significant amblyopia in either eye
17. Women who are pregnant or may become pregnant during the course of the study
18. In the opinion of the investigator the participant might require other ocular surgery within the 12-month follow-up period, unless for further reduction of their IOP
19. Concurrent treatment with topical, nasal, inhaled or systemic steroids
20. Uncontrolled systemic disease that could impact the ability of the participant to attend follow up visits as per the discretion of the investigator

Recruitment start date

01/08/2017

Recruitment end date

01/02/2018

Locations

Countries of recruitment

Italy, United Kingdom

Trial participating centre

Queen's University Belfast
Belfast
BT7 1NN
United Kingdom

Trial participating centre

The University of Genova (Universita Degli Study Di Genova)
Genova
16132
Italy

Sponsor information

Organisation

BELKIN Laser Ltd

Sponsor details

Habarzel 27
Tel Aviv
6971039
Israel

Sponsor type

Industry

Website

Funders

Funder type

Government

Funder name

Horizon 2020 Framework Programme

Alternative name(s)

EU Framework Programme for Research and Innovation H2020, Horizon 2020, H2020

Funding Body Type

government organisation

Funding Body Subtype

federal/national government

Location

Belgium

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

IPD sharing plan
The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Nathan Congdon

Intention to publish date

01/03/2019

Participant level data

Available on request

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

06/11/2017: Ethics approval has been updated 31/08/2017: Ethics information added 10/05/2017: Internal review.